USE OF IL-12 TO GENERATE ENDOGENOUS ERYTHROPOIETIN

• US 20200131240A1
• Filed: 12/23/2019
• Published: 04/30/2020
• Est. Priority Date: 07/27/2011
• Status: Abandoned Application

• Current Assignee: Neumedicines Inc.
• Original Assignee: Neumedicines Inc.
• Inventors: Basile, Lena A.
• Application Number:
  US16/725,896
• Publication Number:
  US 20200131240A1
• Time in Patent Office: Days
• CPC Class Codes: A61K 38/208 IL-12
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 7/06 Antianaemics
• CPC Class Codes: C07K 14/55 IL-2

Abstract

The present invention relates to the use of exogenous interleukin-12 (IL-12) for increasing endogenous production of erythropoietin.

Claims

1. A method for generating endogenous erythropoietin in a subject in need of increasing the levels of erythropoietin in the blood comprising administering a therapeutically effective dose of recombinant IL-12 to the subject, wherein the therapeutically effective dose of IL-12 elevates the endogenous erythropoietin blood concentration.

2. The method of claim 1, wherein the subject is human.

3. The method of claim 1 or 2, wherein the endogenous erythropoietin level in the blood is increased to between about 40 pg/mL and about 5000 pg/mL.

4. The method of any one of claims 1-3, wherein the endogenous erythropoietin level in the blood is increased to between about 40 pg/ml and about 1000 pg/ml.

5. The method of any one of claims 1-4, wherein the endogenous erythropoietin level in the blood is increased to between about 40 pg/ml and about 500 pg/ml.

6. The method of any one of claims 2-5, wherein IL-12 is administered in a dose of between about 5 ng/kg body weight and about 500 ng/kg body weight.

7. The method of any one of claims 2-5, wherein IL-12 is administered in a dose of between about 10 ng/kg body weight and about 320 ng/kg body weight.

8. The method of any one of claims 2-5, wherein IL-12 is administered in a dose of between about 16 ng/kg body weight and about 160 ng/kg body weight.

9. The method of any one of claims 2-5, wherein IL-12 is administered in a dose between about 5 μ

g and 15 μ

g.

10. The method of any one of claims 1-9, wherein IL-12 is administered as a single dose.

11. The method of any one of claims 1-9, wherein IL-12 is administered in multiple doses.

12. The method of any one of claims 1-9 and 11, wherein IL-12 is administered biweekly.

13. The method of any one of claims 1-9 and 11, wherein IL-12 is administered monthly.

14. The method of any one of claims 1-13, wherein the erythropoietin levels are increased for at least about 24 hours following IL-12 administration.

15. The method of any one of claims 1-14, wherein the erythropoietin levels are increased for at least about 36 hours, at least about 2 days, at least about 60 hours (2.5 days), at least about 3 days, at least about 84 hours (3.5 days), at least about 4 days, at least about 108 hours (4.5 days), or at least about 5 days following IL-12 administration.

16. The method of any one of claims 1-15, wherein the erythropoietin levels are increased for at least about 10 days following IL-12 administration.

17. The method of any one of claims 1-16, wherein the recombinant IL-12 is administered to patients with chronic kidney disease before the onset of anemia.

18. The method of any one of claims 1-16, wherein the recombinant IL-12 is administered to patients with chronic kidney disease after the onset of anemia.

19. The method of any one of claims 1-18, wherein the administration of recombinant IL-12 results in improvement in kidney function.

20. The method of any one of claims 1-16, wherein the recombinant IL-12 is administered to HIV patients with anemia.

21. The method of any one of claims 1-16, wherein the recombinant IL-12 is administered to patients with anemia due to the effect of concomitantly administered chemotherapy.

22. The method of any one of claims 1-16, wherein the recombinant IL-12 is administered to patients with anemia due to the effect of concomitantly administered radiation therapy.

23. The method of any one of claims 1-16, wherein the recombinant IL-12 is administered to patients undergoing surgery.

24. The method of any one of claims 1-16, wherein the recombinant IL-12 is administered to patients with anemia and cardiovascular disease.

25. The method of claim 24, wherein administration of recombinant IL-12 improves neovascularization and heart function in patients with cardiovascular disease.

26. The method of any one of claims 1-16, wherein the recombinant IL-12 is administered to patients with brain disorders.

27. The method of claim 26, wherein the brain disorder is selected from the group comprising stroke, ischemia, traumatic brain injury, traumatic spinal cord injury, epilepsy, Alzheimer'"'"'s Disease, Parkinson'"'"'s Disease, amyotrophic lateral sclerosis (ALS), schizophrenia, and multiple sclerosis.

28. The method of any one of claims 1-27, wherein the recombinant IL-12 results in increased blood levels of erythropoietin for improving neovascularization, wound healing, and tissue protection in non-cardiovascular tissue.

29. The method of claim 28, wherein the non-cardiovascular tissue is kidney.